Key result
MASLD clinical updates highlight new diagnostic criteria, risk stratification strategies, and emerging treatments.
Why the study?
New diagnostic criteria, risk stratification, and emerging treatments for metabolic dysfunction–associated steatotic liver disease (MASLD) require clinical updating.
Provides a clinical update on the diagnostic criteria, risk stratification, and emerging treatments for metabolic dysfunction-associated steatotic liver disease (MASLD).
Answers are grounded in this paper and cite their sources.
Prompts review of updated MASLD criteria for risk stratification now; leaves open prospective validation of emerging therapies.
This Clinical Insights discusses new diagnostic criteria, risk stratification, and emerging treatments of metabolic dysfunction–associated steatotic liver disease (MASLD; formerly nonalcoholic fatty liver disease).
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) studied this question. Metabolic dysfunction-associated steatotic liver disease (MASLD) clinical updates highlight new diagnostic criteria, risk stratification strategies, and emerging treatments.
Synapse has enriched 10 related papers. Consider them for comparative context: